TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of renal cell cancer.

Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?

Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive?

Did that patient receive regorafenib at some point during his or her course of metastatic disease?

Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?

Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive?

Did that patient receive regorafenib at some point during his or her course of metastatic disease?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and painful erythema, swelling (Gr 2)>

How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)?

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?

Same patient as above, but the patient develops Grade 1 hand-foot syndrome. What would you do at this time?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and painful erythema, swelling (Gr 2)?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)?

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and painful erythema, swelling (Gr 2)?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)?

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?

Usual starting dose of regorafenib? For a 75 yo pt?

In general, what is the usual starting dose of regorafenib that you use?

What is the starting dose that you use for a 75-year-old patient?

Usual starting dose of regorafenib? For a 75 yo pt?

In general, what is the usual starting dose of regorafenib that you use?

What is the starting dose that you use for a 75-year-old patient?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, colorectal-general surgeons and other healthcare practitioners involved in the management of colorectal cancer.

OVERVIEW OF ACTIVITY